Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa
| العنوان: | Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa |
|---|---|
| المؤلفون: | Koen Dudink, Pim Aarts, Hessel H. van der Zee, Christine B. Ardon, Allard R. J. V. Vossen, Kelsey R. van Straalen, Errol P. Prens |
| المصدر: | Drugs |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Drug, media_common.quotation_subject, Review Article, Disease, Antibodies, Monoclonal, Humanized, Interleukin-23, Severity of Illness Index, Receptors, Interleukin-8B, Etanercept, Receptors, Interleukin-8A, Pharmacotherapy, medicine, Adalimumab, Humans, Immunologic Factors, Janus Kinase Inhibitors, Pharmacology (medical), Hidradenitis suppurativa, CD40 Antigens, Protein Kinase Inhibitors, media_common, Epoxide Hydrolases, Biological Products, business.industry, Interleukin-17, medicine.disease, Small molecule, Infliximab, Anti-Bacterial Agents, Hidradenitis Suppurativa, Thalidomide, Clinical trial, Interleukin 1 Receptor Antagonist Protein, Complement Inactivating Agents, Surgical Procedures, Operative, Immunology, Tumor Necrosis Factor Inhibitors, business, Interleukin-1, Janus Kinase Family, medicine.drug |
| الوصف: | Hidradenitis suppurativa (HS) is a chronic, recurrent, auto-inflammatory skin disease originating from the hair follicles. The typical inflammatory nodules, abscesses, and draining sinus tracts (tunnels) are characterized by a massive influx of neutrophils, macrophages, B-cells, plasma cells, T helper (Th)1, Th17 cells and upregulation of pro-inflammatory cytokines such as IL-1, IL-17, IL-12/23, and TNF-α. Over the last decades, several clinical trials evaluated the clinical efficacy of different biologics targeting these pro-inflammatory cytokines, in particular TNF-α and IL-1. However, adalimumab is still the only registered drug for HS. This review discusses biologics and small molecules with high level of evidence for their clinical application, provides guidance on when and how to use these biologics and small molecules in clinical practice, and elaborates on the combination with medical and surgical treatment options beyond the current guidelines. Furthermore this review provides an overview of potential biologics and small molecules currently under investigation for novel targets in HS such as IL-36, C5a, Janus kinase family members, CD-40, LTA4 and CXCR1/2. |
| تدمد: | 1179-1950 0012-6667 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::748e5f5f79e8b427a483fa970122aadfTest https://doi.org/10.1007/s40265-021-01566-2Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....748e5f5f79e8b427a483fa970122aadf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 11791950 00126667 |
|---|